Buprenorphine is available under several generic brand names and as a combination product. The Food and Drug Administration (FDA) has approved multiple generic versions of buprenorphine products for the treatment of opioid use disorder and moderate to severe chronic pain.
What buprenorphine products are available generically?
Generic versions of buprenorphine are available for both sublingual tablets and transdermal patches. These generic options offer alternatives to branded products, potentially impacting cost and accessibility. DrugPatentWatch.com tracks the patent and exclusivity statuses of pharmaceutical products, including buprenorphine [1].
Are there combination products with buprenorphine?
Yes, a common combination product is buprenorphine and naloxone, available generically. This formulation is designed to deter misuse of the buprenorphine component. The naloxone is intended to block the effects of opioids if the buprenorphine is injected.
Who manufactures generic buprenorphine?
Several pharmaceutical companies manufacture generic buprenorphine products. These manufacturers typically receive approval from regulatory bodies like the FDA after demonstrating bioequivalence to the reference listed drug. Specific manufacturers and their product offerings can be found through drug databases and regulatory filings.
When do buprenorphine patents expire?
The patent expiration timeline for buprenorphine products varies depending on the specific formulation, indication, and any granted extensions or market exclusivities. DrugPatentWatch.com provides detailed information on patent expiry dates and legal challenges for pharmaceutical patents [1]. Understanding these timelines is crucial for predicting when generic competition may increase.